spacer
home > pmps > summer 2002 > unit-dose nasal sprays - systemic delivery through the nose
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Unit-Dose Nasal Sprays - Systemic Delivery Through the Nose

In recent years, the nasal route has received a great deal of attention as a convenient and reliable method for the systemic administration of several compounds. In such cases, the nasal mucosa is used as a portal of entry for drugs into the bloodstream. Conventional drug delivery devices used for the nasal route include metering spray pumps, pressurised metered dose inhalers, squeeze bottles and, to a lesser extent, nasal drops. They are all used in conjunction with liquid formulations (solutions or suspensions). Another unusual but promising approach is to dispense dry powder formulations to/through the nasal mucosa.

Unit-Dose Nasal Sprays

These designate small disposable devices that deliver a limited number of sprays, for example, one or two shots (one per nostril). Another attribute is that they are 'ready to use' - there is no need to shake and/or prime the device prior to use. In addition, they can be used in any position. Examples of commercial pharmaceutical products that use unit-dose nasal spray devices:
Calcitonin, Aventis
Calcitonin, ICN
Inflexal Flu Vaccine, Berna Biotech
Sumatriptan, GlaxoSmithKline


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pierre Carlotti, Marketing Director at Valois' Pharmaceutical Division Pierre Carlotti is the Marketing Director at Valois' pharmaceutical division. From 1996, Pierre Carlotti held the position of Associate Director of Business Development. He has a bachelor and a masters degree in Biology and he also obtained a business degree from the Institut Supérieur du Commerce Extérieur (ISCE) in Paris.
Before working for Valois, Pierre occupied various commercial and marketing positions at Synthelabo and West Pharmaceutical Services.

spacer
Pierre Carlotti
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement